Research Publications

Buprenorphine Research Publications

• Greenwald MK, Herring AA, Perrone J, Nelson LS, Azar P. A Neuropharmacological Model to Explain Buprenorphine Induction Challenges. Ann Emerg Med. 2022 Dec;80(6):509-524

• Heidbreder C, Fudala PJ, Greenwald MK. History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder. Drug Alcohol Depend Rep. 2023 Jan 10;6:100133

• Axeen S et al. Association of daily doses of buprenorphine with urgent health care utilization. JAMA Network Open, 7(9), e2435478.

• NIDA commentary.  Higher doses of buprenorphine may improve treatment outcomes for people with opioid use disorder. (2024, September 25). National Institutes of Health (NIH).

• Chambers LC, Hallowell BD, Zullo AR, Paiva TJ, Berk J, Gaither R, Hampson AJ, Beaudoin FL, Wightman RS. Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl. JAMA Netw Open. 2023 Sep 5;6(9):e2334540.

• Samples H, Nowels MA, Williams AR, Olfson M, Crystal S. Buprenorphine After Nonfatal Opioid Overdose: Reduced Mortality Risk in Medicare Disability Beneficiaries. Am J Prev Med. 2023 Jul;65(1):19-29

• Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, Bagley SM, Liebschutz JM, Walley AY. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study. Ann Intern Med. 2018 Aug 7;169(3):137-145.

• Jones CM, Shoff C, Blanco C, Losby JL, Ling SM, Compton WM. Overdose, Behavioral Health Services, and Medications for Opioid Use Disorder After a Nonfatal Overdose. JAMA Intern Med. 2024 Aug 1;184(8):954-962. 

• Lapham GT, Hyun N, Bobb JF, et al. Nurse Care Management of Opioid Use Disorder Treatment After 3 Years: A Secondary Analysis of the PROUD Cluster Randomized Clinical Trial. JAMA Netw Open. 2024;7(11):e2447447.

• Herring AA, Vosooghi AA, Luftig J, et al. High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder. JAMA Netw Open. 2021;4(7):e2117128.

• Campopiano von Klimo M, Nolan L, Corbin M, et al. Physician Reluctance to Intervene in Addiction: A Systematic Review. JAMA Netw Open.2024;7(7):e2420837.

• Lyons B, Dolezal L. Shame, stigma and medicine. Med Humanit. 2017 Dec;43(4):208-210. doi: 10.1136/medhum-2017-011392. PMID: 29196432; PMCID: PMC5739841.

• Nataraj N, Rikard SM, Zhang K, et al. Public Health Interventions and Overdose-Related Outcomes Among Persons With Opioid Use Disorder. JAMA Netw Open 2024;7(4).

• Nunes EV, Comer SD, Lofwall MR, Walsh SL, Peterson S, Tiberg F, Hjelmstrom P, Budilovsky-Kelley NR. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024 Jun 3;7(6):e2417377

• Englander H, Thakrar AP, Bagley SM, Rolley T, Dong K, Hyshka E. Caring for Hospitalized Adults With Opioid Use Disorder in the Era of Fentanyl: A Review. JAMA Intern Med. 2024 Jun.

• Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health. Substance Abuse and Mental Health Services Administration (US); Office of the Surgeon General (US). 2016 Nov. CHAPTER 5, RECOVERY: THE MANY PATHS TO WELLNESS

• Lina Thors, Linda Öberg, Emma Forsberg, Elisabeth Wigenstam, Andreas Larsson, Anders Bucht, Skin penetration and decontamination efficacy following human skin exposure to fentanyl. Toxicology in Vitro. Volume 67,2020,104914

• Hawk, M., Coulter, R.W.S., Egan, J.E. et al.Harm reduction principles for healthcare settings. Harm Reduct J 14, 70 (2017).

• Harm Reduction at SAMHSA

• Finke J, Chan J. The Case for Supervised Injection Sites in the United States. Am Fam Physician. 2022 May 1;105(5):454-455.

• Greer, A.M., Luchenski, S.A., Amlani, A.A. et al.Peer engagement in harm reduction strategies and services: a critical case study and evaluation framework from British Columbia, Canada. BMC Public Health 16, 452 (2016).

• Ashford, R.D., Curtis, B. & Brown, A.M. Peer-delivered harm reduction and recovery support services: initial evaluation from a hybrid recovery community drop-in center and syringe exchange program. Harm Reduct J15, 52 (2018).

• Jalali, M.S.et al The opioid crisis: a contextual, social-ecological framework. Health Res Policy Sys 18, 87 (2020).

• Rhodes T. Risk environments and drug harms: a social science for harm reduction approach. Int J Drug Policy. 2009 May;20(3):193-201. doi: 10.1016/j.drugpo.2008.10.003. Epub 2009 Jan 14.

• Alex Wodak, Annie Cooney. Effectiveness of sterile needle and syringe programmes..International Journal of Drug Policy, Volume 16, Supplement 1, 2005, Pages 31-44

• Aspinall EJ, Nambiar D, Goldberg DJ, Hickman M, Weir A, Van Velzen E, Palmateer N, Doyle JS, Hellard ME, Hutchinson SJ. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol. 2014 Feb;43(1):235-48. 

• Khan, G.K., Harvey, L., Johnson, S. et al.Integration of a community-based harm reduction program into a safety net hospital: a qualitative study. Harm Reduct J 19, 35 (2022).

• Grande LA, Hutch T, Jack K, Mironov W, Iwuoha J, Muy-Rivera M, Grillo J, Martin SA, Herring A. Ketamine-assisted buprenorphine initiation: a pilot case series. Addict Sci Clin Pract. 2024 Aug 29;19(1):60.

• Stroud C, Posey Norris SM, Bain L, editors. The History of Methadone and Barriers to Access for Different Populations (2022). In Methadone Treatment for Opioid Use Disorder: Improving Access Through Regulatory and Legal Change: Proceedings of a Workshop. Washington (DC): National Academies Press (US); 2022 Jul 15.

• Defalque RJ, Wright AJ. The early history of methadone. Myths and facts. Bull Anesth Hist. 2007 Oct;25(3):13-6. 

• Suarez EA, Bateman BT, Straub L, Hernández-Díaz S, Jones HE, Gray KJ, Connery HS, Davis JM, Lester B, Terplan M, Zhu Y, Vine SM, Mogun H, Huybrechts KF First Trimester Use of Buprenorphine or Methadone and the Risk of Congenital Malformations. JAMA Intern Med. 2024 Mar 1;184(3):242-251

• High-Dose Naloxone Formulations Are Not as Essential as We Thought – Reassesses naloxone dosing strategies.

• Impact of a Community-Based Naloxone Distribution Program – Examines naloxone's life-saving impact on opioid overdose deaths.

• Pharmacy Naloxone Standing Orders and Opioid Fatality Rates – Evaluates how pharmacy access to naloxone reduces fatalities over time.

• Overdose Prevention Centres as Spaces of Safety, Trust, and Inclusion – A realist review of the benefits of overdose prevention centers.

• Korthuis PT, McCarty D, Weimer M, Bougatsos C, Blazina I, Zakher B, Grusing S, Devine B, Chou R. Primary Care-Based Models for the Treatment of Opioid Use Disorder: A Scoping Review. Ann Intern Med. 2017 Feb 21;166(4):268-278

• Alford DP, LaBelle CT, Kretsch N, Bergeron A, Winter M, Botticelli M, Samet JH. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011 Mar 14;171(5):425-31.

• Johnson M, Cosentino D, Fuehrlein B. A detox dilemma beyond benzodiazepines; clonidine's quandary in alcohol withdrawal management. Am J Addict. 2025 Jan;34(1):101-103.